ArticleBrain communications2026
Neurophysiological, imaging and neurobiological markers of central fatigue in multiple sclerosis.
Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central fatigue affects 80% of patients with multiple sclerosis, with 60% of them claiming it as the most disabling symptom. Current research often independently explores neurophysiological, structural, or functional imaging and biological underpinnings of fatigue, thus lacking a multidimensional perspective. Here, we used a multidimensional approach to investigate the functional, structural and biological underpinnings of fatigue in MS and to assess the relative contribution of each factor. A cross-sectional study was conducted with 41 patients with relapsing-remitting multiple sclerosis and 21 healthy controls (female 14) (HC). MS patients were recruited by including only those with an Expanded Disability Status Scale score < 4, and were categorized as fatigued (MS-F: 19, Female 13, FSS ≥ 4) or non-fatigued (MS-NF: 22, Female 11, FSS < 4). Over five phases, participants underwent Transcranial Magnetic Stimulation, resting-state Electroencephalography, structural and functional Magnetic Resonance, clinical assessments, and blood tests for neurofilament light chain, serum glial fibrillary acidic protein and cytokine levels. Data were analysed using both non-parametric and parametric tests, based on the data distribution. Finally, a decision-tree model was applied to predict patient group assignment. Neurophysiologically, the two patient groups differed in several domains. Those with fatigue had increased θ-band EEG power in frontocentral regions with eyes open. Transcranial Magnetic Stimulation findings indicated significantly lower intracortical facilitation in the MS-F group. Neuroimaging revealed stronger functional connectivity between nodes of the Default Mode Network, between the left temporal node and the right prefrontal node, in the MS-F group. Furthermore, fractional anisotropy via Diffusion Tensor Imaging showed reduced white matter integrity in the corticospinal tracts and corpus callosum in these patients. No significant differences were observed in lesion load, brain volumes, clinical/psychological measures, or blood sample findings linked with neurodegeneration or inflammation; the only psychological variable that differed between the two groups was the depression scale score, with MS-F patients reporting higher scores than MS-NF patients. The decision tree analysis identified both ICF and significantly lower fractional anisotropy values as the most accurate predictors of fatigue, with a classification accuracy of 84.2%. Results highlight the importance of a multidisciplinary approach in defining central fatigue in multiple sclerosis, which would emerge through subtle, subclinical, regional abnormalities of myelin integrity and clearly manifest neurophysiological evidence of impaired glutamatergic activity in motor areas. They also suggest possible biomarkers for the diagnosis of fatigue, possibly useful for eventual targeting novel neuromodulatory treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.